Disney and Lucasfilm have confirmed that the animated series Maul: Shadow Lord will return for a second season in 2027.
The show, which follows the former Sith apprentice to Darth Sidious, has garnered praise for its mature narrative and dark aesthetic.
Critics and audiences have frequently compared the project to the live-action series Andor due to its nuanced writing and tone.
According to “ScreenRant”, the series is currently considered one of the most anticipated projects on the franchise’s horizon.
The first season of the show functioned primarily as a narrative setup for the titular character.
During those initial episodes, Maul worked to reclaim his Shadow Collective and influence characters like Devon Izara toward the dark side of the Force.
The upcoming season is expected to focus on the execution of these plans, including a potential coup involving the Crimson Dawn organization.
The production features a distinct 3D animation style that serves as a direct continuation of the character’s role in the conclusion of The Clone Wars.
Creator Dave Filoni and his team have utilized this era to explore the dark side of the Force in greater depth.
The series is notable for being one of the few projects in the franchise to center its story on a villain as the primary protagonist.
The first season received near-universal acclaim for its visual quality and mature storytelling.
As the studio shifts its broader focus toward upcoming theatrical films, the animated project remains a significant component of the television slate.
The show is listed as a product of the Clone Wars era of television and maintains a connection to that established history.
With the foundation established in the first season, the creative team aims to expand the scope of the underworld elements in the next installment.
Fans can expect the return of the series on Disney+ in 2027 as the franchise balances its transition back to the silver screen.
The project continues to be viewed as a high-performing asset for the studio following its initial success.